Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)

Laurent Garderet, Myriam Labopin, Norbert Claude Gorin, Emmanuelle Polge, André Baruchel, Giovanna Meloni, Juan Ortega, Jaak Vossen, Donald Bunjes, Guy Leverger, Didier Blaise, Augustin Ferrant, Mats Brune, Eric Dore, Helmut Gadner, Felix Zintl, Isaac Yaniv, Giorgio Dini, Francesco Frassoni

Research output: Contribution to journalArticle

Abstract

Acute megakaryoblastic leukemia (M7 AML) is a highly aggressive disease. We evaluated outcomes in 57 children (11 with Down syndrome) and 69 adults with M7 AML after first complete remission (CR1) following autologous or HLA-identical allogeneic transplantation. Characteristics of the recipients of autologous transplants (38 children, 37 adults) were, respectively: median age, 1.7 and 46 years; non-total body irradiation (non-TBI) conditioning regimen, 97% and 70%; bone marrow as stem cell source, 74% and 43%. Characteristics of the recipients of allogeneic transplants (19 children, 32 adults) were, respectively: median age, 2.8 and 37 years; non-TBI regimen, 63% and 42%; bone marrow as stem cell source, 95% and 69%. Autologous transplantation benefited children more; the relapse rate was high in adults. Results for autologous transplantation were (children and adults, respectively): engraftment, 90% and 100%; 3-year treatment-related mortality (TRM) rate, 3% and 8%; relapse rate, 45% and 64%; leukemia-free survival (LFS) rate, 52% and 27%; overall survival (OS) rate, 61% and 30%. After allogeneic transplantation, TRM was fairly low in children and adults, and relapse rates were lower than after autologous transplantation. Results for allogeneic transplantation were, respectively: engraftment, 95% and 90%; TRM, 0% and 26%; relapse rate, 34% and 28%; LFS, 66% and 46%; OS, 82% and 43%). We conclude that M7 AML patients in CR1 (except children with Down syndrome, who already have better outcomes) can benefit from transplantation.

Original languageEnglish
Pages (from-to)405-409
Number of pages5
JournalBlood
Volume105
Issue number1
DOIs
Publication statusPublished - Jan 1 2005

    Fingerprint

ASJC Scopus subject areas

  • Hematology

Cite this

Garderet, L., Labopin, M., Gorin, N. C., Polge, E., Baruchel, A., Meloni, G., Ortega, J., Vossen, J., Bunjes, D., Leverger, G., Blaise, D., Ferrant, A., Brune, M., Dore, E., Gadner, H., Zintl, F., Yaniv, I., Dini, G., & Frassoni, F. (2005). Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 105(1), 405-409. https://doi.org/10.1182/blood-2004-03-1103